Skip to content
drillr.ai

KURA

Kura Oncology, Inc.

NASDAQ · USHealthcareBiotechnology
$10.68-1.66%

Price as of Jul 20, 2026

KURA news

Kura Oncology, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

    – Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients – – Updated data expected to support darlifarnib’s potential to enhance VEGFR-targeted therapy in ccRCC – – Global randomized Phase 1b study comparing darlifarnib plus cabozantinib versus cabozantinib alone is ongoing – – Results continue to support darlifarnib as a precision combination agent across multiple targeted therapy classes –

    Globe Newswire ·

  2. Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, July 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on July 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 68,750 shares of common stock to five (5) new employees under the Company’s 2

    Globe Newswire ·

  3. Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

    – 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial – – 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML – – High rates of MRD negativity among NPM1-m AML responders assessed by both local assays and central testing – – Median OS not reached in either NPM1-m or KMT2A-r population with median follow-up of 17.6 months and 11.0 months, respectively – – 12-month survival rate, remission rates, MRD negativi

    Globe Newswire ·

  4. Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

    – Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients – – Clinical activity observed in both KRAS inhibitor-naïve and KRAS inhibitor-pretreated patients – – Preclinical data support broad applicability across the evolving RAS inhibitor landscape, including mutant-selective, pan-KRAS and RAS(ON) multi-selective inhibitors –

    Globe Newswire ·

  5. Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

    – 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose – – Central MRD negativity in 75% of CRc responders with no prior venetoclax exposure; median CRc duration was 9.2 months – – Median OS not reached after median follow up of 10.7 months in patients with no prior venetoclax exposure – – Combination was well tolerated, with low rates of differentiation syndrome and QTc prolongation observed – SAN DIEGO

    Globe Newswire ·

  6. Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

    – Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients – – ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients – – Results reinforce darlifarnib’s potential as a precision combination agent across targeted therapies – – Clear clinical activity in KRASi-experienced patients and manageable safety profile – – Virtual investor event on June 3, 2026, at 12:15 p.m. PT / 3:15 p.m. ET – SAN DIEGO, May 26,

    Globe Newswire ·

  7. Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit

    SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA) today announced its participation in the TD Cowen 7(th) Annual Oncology Innovation Summit: Insights for ASCO & EHA. Kura management is scheduled to participate in a virtual fireside chat at 1:30 p.m. ET / 10:30 a.m. PT on May 26, 2026. The live webcast and archived replay of the event may be accessed on the Investors section of the Company’s website at www.kuraoncology.com. About Kura Oncology Kura Oncology is a bi

    Globe Newswire ·

  8. Kura Oncology Reports First Quarter 2026 Financial Results

    – $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching and combination adoption, reflect strong early momentum – – Broad and rapid payer access achieved, with > 93% coverage and favorable positioning across > 12 million lives – – Multiple 2026 data readouts expected to support ziftomenib as a broadly combinable backbone across AML – – $580.8 million in cas

    Globe Newswire ·

  9. Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

    – Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML – – High CRc rates (90–96%) with deep MRD negativity (> 80%) across both subtypes – – Durable responses with median duration of CRc not reached in NPM1-m patients at ~15 months median follow-up – – Phase 3 KOMET-017 trial currently enrolling with potential for accelerated FDA review in 2028 – – Virtual Kura investor call on June 3 at 8:00 a.m. ET – SAN DIEGO, May 12, 2026 (GLOB

    Globe Newswire ·

  10. Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

    Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treated with cabozantinib, with tumor shrinkage observed in 75% of patients Responses observed in heavily pretreated patients, including those with stable disease on prior cabozantinib Durable treatment durations reaching 56 weeks, with one-third of patients remaining on therapy at time of data cut-of

    Globe Newswire ·

  11. Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results

    – KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, supporting ongoing development plans targeting up to 50% of AML patients – – Orange Book listing of patents extending up to 2044 reinforces long-term value for KOMZIFTI – – FIT-001 Phase 1b dose expansion initiated for darlifarnib and cabozantinib combination in advanced renal cell carcinoma – – Mul

    Globe Newswire ·

  12. Kura Oncology to Participate in Three Upcoming Investor Conferences

    For best results when printing this announcement, please click on link below: https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260225:nGNXc5LNnx&default-theme=true SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the following investor conferences: TD Cowen Health Care Conference Ma

    Globe Newswire ·